Could a 7-Day antibiotic course every 8 weeks tame bronchiectasis Flare-Ups?
NCT ID NCT07274020
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether taking the antibiotic moxifloxacin for 7 days every 8 weeks (for a year) can reduce lung infection flare-ups in people with non-cystic fibrosis bronchiectasis. 140 adults who have had at least two flare-ups in the past year will be randomly assigned to either the intermittent moxifloxacin regimen plus standard care, or standard care alone. The main goal is to see if the antibiotic schedule lowers the number of exacerbations.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Moxifloxacin (an antibiotic taken by mouth)
- What this could lead to
- If it works, this could give doctors a new way to reduce lung infections and hospital visits for people with bronchiectasis.
- What could go wrong
- This is a single-center trial with 140 people, so results may not apply to everyone. Moxifloxacin can cause serious side effects like tendon damage and nerve problems, and long-term antibiotic use may lead to drug resistance.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 140 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Dec 2025
An estimate. Start dates often move.
- Expected to finish
-
Jan 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adults ≥18 years of age. * Confirmed diagnosis of non-cystic fibrosis bronchiectasis by high-resolution CT (HRCT). * History of ≥2 bronchiectasis exacerbations in the previous 12 months. Exclusion Criteria: * Diagnosis of cystic fibrosis-related bronchiectasis. * Known hypersensitivity or contraindication to fluoroquinolones (including moxifloxacin). * Severe hepatic impairment or severe renal impairment (eGFR \<30 mL/min/1.73 m²). * Pregnancy or breastfeeding. * History of significant QT prolongation, arrhythmia, or concurrent use of QT-prolonging drugs. * Use of long-term suppressive antibiotics for bronchiectasis in the past 3 months.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bronchiectasis, non-cystic fibrosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Assiut University hospital
Asyut, Asyut Governorate, 71515, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.